GlaxoSmithKline's diabetes drug Avandia (rosiglitazone) was approved by the FDA in 1999. A 2007 meta-analysis by cardiologist Steven Nissen, published in the New England Journal of Medicine, found that Avandia was associated with a 43% increased risk of myocardial infarction. Senate Finance Committee investigations in 2010 found that GSK had internal evidence of cardiovascular risk years before the Nissen publication and had not disclosed it to regulators. GSK settled with the US Department of Justice for $3 billion in 2012 — at the time the largest healthcare fraud settlement in US history — covering Avandia and other products. The FDA restricted Avandia to patients with no other options in 2010 and lifted the restrictions only in 2013 after further review.